Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/10/2022* -- Results Q3 2022 -- -0.51 --
08/03/2022 -- Results Q2 2022 -0.48 -0.50 3.03%
05/05/2022 -- Results Q1 2022 -0.44 -0.43 -3.12%
02/28/2022 -- Results Q4 2021 -0.35 -0.41 14.63%
11/10/2021 -- Results Q3 2021 -0.24 -0.17 -45.45%
08/03/2021 -- Results Q2 2021 -0.13 -0.13 0.00%
08/03/2021 09:00 EST Earnings Call Q2 2021 -- -- --
04/29/2021 -- Results Q1 2021 -0.09 -0.08 -12.50%
*Estimated Date/Time

Earnings

Next Report Date 11/10/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since 126.1%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
URL https://www.cassavasciences.com
Investor Relations URL http://investor.paintrials.com/
HQ State/Province Texas
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Dec. 13, 2012

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date Dec. 13, 2012
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-13.79%
-67.42%
0.22%
-78.75%
511.8%
31.15%
540.8%
-4.30%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-23.87%
66.00%
45.78%
148.8%
-26.02%
-9.43%
116.2%
-24.31%
29.49%
652.7%
-28.90%
-18.69%
-51.55%
66.03%
108.5%
221.1%
-40.48%
--
--
--
15.00%
-70.65%
-72.96%
-28.90%
-55.68%
--
--
-66.88%
-57.90%
24.74%
76.67%
16.04%
-65.04%
As of September 30, 2022.

Profile

Edit
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
URL https://www.cassavasciences.com
Investor Relations URL http://investor.paintrials.com/
HQ State/Province Texas
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Dec. 13, 2012

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
XPH 10.23M USD 4.83%
IBRN 216219.0 USD 4.34%
MEME 36606.00 USD 3.96%
PILL 328142.0 USD 3.20%
BBC 183780.0 USD 1.08%
IHE 2.631M USD 0.68%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SAVA Tweets